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Abstract
Objective: To evaluate clinical and laboratory profiles of patients with type 1 diabetes mellitus in three public 
hospitals in São Paulo, Brazil, since type 1 diabetes mellitus is a chronic illness that occurs mainly in the pediatric 
age group in the Brazilian population.
Methods: Cross-sectional study with patients followed up in reference centers in São José do Rio Preto (FAMERP), 
Campinas (UNICAMP) and São Paulo (Conjunto Hospitalar do Mandaqui). Data about gender, age, diabetes duration, 
daily insulin dose, number of daily insulin injections, and glycosylated hemoglobin (HbA1c) were analyzed. 
Results: Two hundred and thirty-nine patients (131 females) were evaluated; mean age was 13.1±4.7 years and 
mean diabetes duration was 6.6±4.2 years. Daily insulin doses ranged from 0.1 to 1.78 units/kg/day (0.88±0.28), 
and 180 (74.7%) patients had two daily injections. HbA1c ranged from 4.6 to 17.9% (10.0±2.3%). 
Conclusions: Although the hospitals included in this study are excellence centers for the follow-up of patients 
with diabetes in three municipalities in the state of São Paulo, one of the most developed states in Brazil, blood 
glucose control evaluated according to HbA1c was not adequate. Findings confirm that, despite the efforts of all the 
professionals involved, great challenges still lie ahead.
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Introduction
Type 1 diabetes mellitus (T1DM) is one of the most 
serious endocrine diseases of childhood and adolescence. 
Its incidence, which varies between countries and different 
ethnic groups, ranges from 0.1 to 37.4/100,000 among 
children 0 to 14 years.1
The purpose of diabetes treatment is to achieve 
metabolic balance and to ensure patient well being. 
Evidence shows that improved blood glucose control reduces 
the risk of chronic complications and is associated with 
better quality of life.2
Intensive insulin regimens have been suggested, but 
their use alone does not ensure that expected optimal 
blood glucose control is achieved. Factors such as diabetes 
education, support of healthcare team, self-monitoring, and 
patient’s satisfaction may be more importantly associated 
with improved disease control than intensive treatment.3 
1. Department of Pediatrics and Pediatric Surgery, Pediatric Endocrinology Section, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do 
Rio Preto, SP, Brazil.
2. Department of Pediatrics, Pediatric Endocrinology Unit, School of Medicine, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
3. Department of Pediatrics, Pediatric Endocrinology Unit, Conjunto Hospitalar do Mandaqui, São Paulo, SP, Brazil.
No conflicts of interest declared concerning the publication of this article.
Suggested citation: Jose LP, Cardoso-Demartini AA, Liberatore Junior RD, Paulino MF, de Lemos-Marini SH, Guerra-Júnior G, et al. Clinical and laboratory profile 
of pediatric and adolescent patients with type 1 diabetes. J Pediatr (Rio J). 2009;85(6):490-494.
Manuscript submitted Jun 18 2009, accepted for publication Aug 26 2009.
doi:10.2223/JPED.1942
Clinical and laboratory profile of pediatric
and adolescent patients with type 1 diabetes
Laura Pereira da Silva Jose,1 Adriane de A. Cardoso-Demartini,1 Raphael D. R. Liberatore Junior,1 
Maria Fernanda Vanti Macedo Paulino,2 Sofia Helena Valente de Lemos-Marini,2 
Gil Guerra-Júnior,2 Albertina Gomes Rodrigues3
Jornal de Pediatria - Vol. 85, No. 6, 2009  491
The recommendations made in the Diabetes Control and 
Complications Trial (DCCT) demand important changes in 
patient’s behavior: self-monitoring of capillary blood glucose 
three to four times a day, four daily insulin injections or 
use of an insulin pump, changes in eating habits, practice 
of planned physical activities, and adjustment of insulin 
doses according to dietary intake and exercise.4
The DCCT demonstrated that intensive treatment of 13- 
to 39-year-old patients delays the onset and progression 
of retinopathy, nephropathy and diabetic neuropathy, 
and that there is an association between blood glucose 
levels, glycosylated hemoglobin (HbA1c) and microvascular 
complications in patients with diabetes.4 Hypoglycemia is 
a limiting factor to intensive glycemic control, especially in 
small children who are under risk of cognitive alteration 
after repetitive hypoglycemic episodes.5 Although the risk of 
hypoglycemia was greater in patients undergoing intensive 
therapy, benefits outweighed the risk of hypoglycemia6-8 
and now the basal-bolus regimen with rapid-acting 
analogs (aspart, lispro) given in bolus generally reduce 
hypoglycemia episodes and postprandial glycemia levels, 
while basal insulin analogs (detemir, glargina) tend to 
reduce particularly the number of episodes of nocturnal 
hypoglycemia.5 
Intensive diabetes treatment is based on the adaptation 
of insulin regimens to the results of blood glucose self-
monitoring, and should not be determined only by the number 
of daily insulin injections.9 Strict clinical and laboratory 
control and individualized treatment should be determined 
by a multidisciplinary team. Moreover, patients and their 
families should receive education about the treatment and 
be prepared to adhere to it.
This study, which was conducted to improve patient 
follow-up, evaluated the clinical and laboratory profiles of 
children and adolescents with T1DM in three public hospitals 
that are excellence centers for patients with T1DM in the 
state of São Paulo, Brazil.
Patients and methods
This cross-sectional study was conducted in the middle of 
2006, with patients followed up in T1DM reference centers in 
São José do Rio Preto (FAMERP), Campinas (UNICAMP) and 
São Paulo (Conjunto Hospitalar do Mandaqui). In those three 
centers, a multidisciplinary approach was used, as pediatric 
endocrinologists, nurses, nutritionists, psychologists, and 
educators work together in consultations four times a year, 
free emergency and telephone access. The follow-up was 
carried out beginning with the group meeting with the team 
and subsequently individual appointment with the doctor.
All patients and at least one caregiver received individual 
orientation from the professionals of the team (psychologist, 
nutritionist and nurse) relative to use of insulin, finger 
glycemic tests and food plan. There was no orientation as 
to carbohydrate counting.
The patients were encouraged to alter their insulin dosage 
based on the results of glycemic tests. Ophthalmologic 
evaluation and 24 h microalbuminuric dosages were carried 
out annually in those with more than 5 years of diabetes.
The diagnosis of T1DM was made following international 
criteria and excluded all other kinds of diabetes. No patient 
had retinopathy or nephropathy.
For all patients NPH insulin, syringes and glucose monitor 
strips are provided by the State. Insulin analogues, pumps 
and pens are not provided.
The medical records of 239 patients were reviewed, and 
data were collected about gender, age, disease duration, 
daily insulin dose, number of daily insulin injections, use 
of glucometer for self-monitoring of blood glucose levels, 
and level of HbA1c. All data were collected from the last 
visit records.
Level of HbA1c was measured by high performance liquid 
chromatography (HPLC) at a reference interval of 4.6 to 
6.5%. According to the International Society of Pediatric 
and Adolescent Diabetes (ISPAD), optimal HbA1c levels are 
≤ 7.5%; suboptimal, between 7.6 and 9.0%; and poor (or 
high risk), greater than 9.0%.4,9  For statistical analysis in this 
study, results were divided into two groups: poor control = 
HbA1c > 9.0%; and good control = HbA1c ≤ 9.0%.
The research protocol was approved by the Institutional 
Review Board from São José do Rio Preto Medical School 
with no necessity of a consent form.
Data were described and analyzed with a parametric 
test (Student’s t), and with a nonparametric test (chi-
square) for non-normally distributed values. Linear and 
multiple regression tests were used to study the behavior 
of two or more variables simultaneously to detect possible 
associations between variation of one variable as a function 
of variation of one or more of the other variables. The level 
of type I error was α = 5%, and p < 0.05 was considered 
significant.
Results
The medical records of 239 patients (131 female patients) 
were reviewed. Mean age was 13.1±4.7 years (3.0 to 26.2 
years), and mean T1DM duration was 6.6±4.2 years (0.4 
to 18.5 years).
Insulin doses ranged from 0.1 to 1.78 units/kg/day 
(0.88±0.28). The number of daily insulin injections was 
two for 179 (74.9%) patients, one for 28 (11.7%), and 
three for 32 (13.4%).
Sixty-four patients (26.8%) used only NPH insulin; 78 
(32.6%) used premixed insulin (70/30; 80/20; 90/10); 44 
(18.4%) used NPH and regular insulin; and 52 (21.8%), 
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T1DM control (HbA1c) Good (≤ 9.0%) Poor (> 9.0%)
Number of patients 93 (38.9%) 146 (61.1%)*
Gender 44 males, 55 females 64 males, 82 females
Age (years) 11.9±5.3 (3.0-23.2) 13.8±4.1 (3.00-22.6)
T1DM duration (years) 5.7±4.2 (0.4-17.2) 7.2±4.1 (0.5-18.5)
Daily insulin dose (units/kg/day) 0.85±0.28 (0.17-1.78) 0.90±0.27 (0.10-1.68)
HbA1c (%) 7.8±1.0 (4.6-9.0) 11.4±1.8 (9.1-17.9)*
One daily injection 18 (19.4%) 10 (6.8%)
Two daily injections 65 (69.9%) 114 (78.1%)
Three daily injections 10 (10.7%) 22 (15.1%)*
Table 1 - Distribution of patients with diabetes according to HbA1c level
HbA1c = glycosylated hemoglobin; T1DM = type 1 diabetes mellitus.
* p < 0.05.
used NPH and lispro insulin. Only one patient (0.4%) used 
glargine and lispro insulin.
Only two patients (0.8%) did not perform capillary 
blood glucose self-monitoring because they did not have a 
glucometer at home.
HbA1c ranged from 4.6 to 17.9% (10.0±2.3%), and 
there were no significant differences between genders 
(females = 10.1±2.4%; males = 9.9±2.2%; p = 0.49). 
T1DM control was good for 93 (38.9%) patients, and 
poor for 146 (61.1%). In both groups, most patients had 
two daily insulin injections (Table 1), and, unexpectedly, 
patients that had three daily injections had a greater 
mean HbA1c (p = 0.007).
However, HbA1c was significantly lower in patients that 
used NPH insulin and lispro than in patients that used 
only NPH, premixed insulin or NPH and regular insulin 
(p = 0.0005) (Table 2).
In this group, multiple regression analysis revealed 
that three daily injections (p = 0.008), doses greater than 
0.8 units/kg/day (p = 0.001), and disease duration longer 
than 5 years (p = 0.04) were associated with poorer 
T1DM control as assessed by level of HbA1c.
 Only NPH Premixed NPH + Regular NPH + Lispro
Type of insulin (n = 64) (n = 78) (n = 44) (n = 52)
Gender 30 males, 37 males, 17 males, 24 males,
 34 females 41 females 27 females 28 females
Age (years) 12.9±4.4 12.6±4.5 17.0±4.2 10.8±3.6
 (3.2-23.2) (3.8-22.6) (8.1-26.2) (3.0-19.0)
T1DM duration (years) 6.7±4.2 7.1±4.4 8.5±3.6 4.1±3.0
 (0.4-17.2) (0.8-18.5) (0.7-16.0) (0.5-10.0)
Daily insulin dose 0.76±0.25 0.88±0.21 0.97±0.29 0.96±0.32
(units/kg/day) (0.17-1.39) (0.56-1.78) (0.36-1.68) (0.10-1.64)
One daily injection 8 (12.5%) 0 (0) 0 (0%) 19 (36.5%)
Two daily injections 53 (82.8%) 68 (87.2%) 27 (61.4%) 29 (55.8%)
Three daily injections 3 (4.7%) 10 (12.8%) 17 (38.6%) 4 (7.7%)
HbA1c (%) 10.5±2.7 10.5±1.9 10.0±2.1 8.7±2.1
 (5.5-17.9) (7.2-14.9) (6.8-16.9) (4.6-14.5)*
Table 2 - Distribution of patients with diabetes according to type of insulin
HbA1c = glycosylated hemoglobin; T1DM = type 1 diabetes mellitus.
* p < 0.05 - ANOVA.
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Discussion
In recent years, the concept of metabolic control has 
gained importance in the analysis of onset and progression 
of chronic complications of diabetes, and the concept of 
dissociation between metabolic control and onset of these 
complications was left behind in the history of diabetology. 
The DCCT concluded that there is a reduction of about 
60% in the risk of retinopathy, nephropathy and diabetic 
neuropathies in patients with good control.4 Recent studies 
also found a reduction of 42% in cardiovascular risk in 
patients that undergo intensive treatment for diabetes 
mellitus.10 Moreover, each 1% reduction in the levels of 
HbA1c significantly affects the prevention of microvascular 
complications.11
The objective of diabetes treatment is to keep HbA1c 
at a level that prevents occurrence of severe and frequent 
hypoglycemia.5 In this study, mean HbA1c was 10.0±2.3%, 
and most (61.1%) patients had levels greater than 9.0%. 
These findings indicate a high risk of chronic complications 
and poor metabolic control despite self-monitoring and the 
efforts of the multidisciplinary medical team that assisted 
the patients.
The international experience with this age is not very 
different. Recent surveys have shown that it is very difficult 
to maintain HbA1c levels under the eights even in reference 
centers. A recent Brazilian survey showed that 90% of 979 
young adults in different places around the country were 
not under good control.12,13
More than only type of insulin, number of insulin shots 
or finger glucose dosages seem to be important. The 
team approach, frequent educational meetings and also 
psychological issues are very important, mainly in the 
adolescent group.12,14,15
A great number of patients (32.6%) used premixed 
insulins, which have already been reported to be associated 
with poor metabolic control in adolescents.11 However, 
mean HbA1c in this group of patients was similar to that 
of patients that used only NPH or NPH and regular insulin. 
The group with the lowest mean HbA1c was that of patients 
that used NPH and lispro insulin, which may be explained 
by lispro’s greater efficacy in rapidly reducing postprandial 
glucose levels.
The same results were found in other studies. Use of 
NPH insulin with rapid analogues in the same shot reduces 
HbA1c by reducing postprandial glucose levels. The best way 
to control T1DM patients is the basal/bolus approach, which 
was not being used in this study group.16,17
Most patients (74.9%) had two daily insulin injections 
and those that had three injections had greater mean 
HbA1c. This is the group of patients in whom the disease 
duration was longer. We could speculate that as those 
patients were the oldest (adolescents), metabolic control 
was decreased by poor adherence to the treatment, as 
reported by other authors.15
Conclusion
Although this study was conducted with patients followed 
up in reference hospitals of three cities in one of the most 
developed Brazilian state, optimal blood glucose control, 
evaluated according to level of HbA1c, was not achieved when 
only the number of daily insulin injections or the daily insulin 
dose was increased. The data showed that multidisciplinary 
teams still face great challenges to prescribe individualized 
treatments that respond to the needs of each patient with 
T1DM, and suggest that education should be the basis of 
successful treatments.
We also believe that new approaches, such as multiple 
insulin doses, insulin pumps and carbohydrates counting, 
could be helpful in improving metabolic control. Economic 
and social issues must be confronted, a major challenge 
for coming years.
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